Investor Sio Capital Management, LLC
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Sio Capital Management, LLC . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Add This Fund
to your dashboard

Date Form Target Prev
Shares		 Current
Shares		 Change
(Percent)		 Ownership
(Percent)		 Change
(Percent)
2025-08-13 13G/A DRUG / Bright Minds Biosciences Inc. 507,562 512,338
2025-08-13 13G/A PMVP / PMV Pharmaceuticals, Inc. 3,735,396 3,735,396
2025-08-13 13G ALGS / Aligos Therapeutics, Inc. 355,937
2025-08-13 13G NMTC / NeuroOne Medical Technologies Corporation 3,523,663
2025-08-13 13G/A AVR / Anteris Technologies Global Corp. 3,464,965 2,934,027
2025-08-13 13G/A APRE / Aprea Therapeutics, Inc. 276,603 279,369
2025-04-08 13G VXRT / Vaxart, Inc. 11,515,315 5,583,448
2025-04-08 13G QTTB / Q32 Bio Inc. 697,413 0
2025-04-08 13G PMVP / PMV Pharmaceuticals, Inc. 3,572,167 3,735,396
2025-04-08 13G/A APRE / Aprea Therapeutics, Inc. 280,000 276,603
2025-04-08 13G/A VTYX / Ventyx Biosciences, Inc. 4,046,797 2,582,655
2025-04-08 13G AVR / Anteris Technologies Global Corp. 3,465,005 3,464,965
2025-04-08 13G DRUG / Bright Minds Biosciences Inc. 451,793 507,562
2025-02-10 13G VTYX / Ventyx Biosciences, Inc. 4,046,797
2025-02-10 13G PMVP / PMV Pharmaceuticals, Inc. 3,572,167
2025-02-10 13G VXRT / Vaxart, Inc. 11,515,315
2025-02-10 13G/A MODD / Modular Medical, Inc. 2,110,260 251,990
2025-02-10 13G QTTB / Q32 Bio Inc. 697,413
2025-02-10 13G AVR / Anteris Technologies Global Corp. 3,465,005
2025-02-10 13G DRUG / Bright Minds Biosciences Inc. 451,793
2025-02-10 13G/A 280,000 276,603
2024-02-14 13G GRCL / Gracell Biotechnologies Inc. - Depositary Receipt (Common Stock) 25,007,900
2024-02-14 13G/A MODD / Modular Medical, Inc. 1,091,479 2,110,260
2024-02-14 13G APRE / Aprea Therapeutics, Inc. 280,000
2023-02-13 13G MODD / Modular Medical, Inc. 1,091,479
2022-02-10 13G/A SLRX / Salarius Pharmaceuticals, Inc. 1,657,242 1,354,291
2022-02-10 13G/A CLRB / Cellectar Biosciences, Inc. 2,331,123 0
2022-02-10 13G/A CRIS / Curis, Inc. 4,756,438 3,866,645
2021-02-16 13G/A LRMR / Larimar Therapeutics, Inc. 2,283,164 188,661
2021-02-16 13G CLRB / Cellectar Biosciences, Inc. 2,331,123
2021-02-16 13G SLRX / Salarius Pharmaceuticals, Inc. 1,657,242
2021-02-16 13G CRIS / Curis, Inc. 4,756,438
2020-02-14 13G/A BNGO / Bionano Genomics, Inc. 714,842 1,210,821
2020-02-14 13G LRMR / Larimar Therapeutics, Inc. 2,283,164
2020-02-14 13G TRIL / Trillium Therapeutics Inc 2,751,186
2020-02-14 13G/A BBI / Brickell Biotech Inc 0
2020-02-14 13G/A ACHV / Achieve Life Sciences, Inc. 597,373 0
2019-02-14 13G ACHV / Achieve Life Sciences, Inc. 597,373
2019-02-14 13G BBI / Brickell Biotech Inc 1,615,887
2019-02-14 13G BNGO / Bionano Genomics, Inc. 714,842
2019-02-14 13G ACHV / Achieve Life Sciences, Inc. 597,373
2018-02-14 13G QTNT / Quotient Ltd 2,237,771 1,426,125
2018-02-14 13G CBIO / Crescent Biopharma, Inc. 168,000 202,281
2017-04-19 13G CBIO / Crescent Biopharma, Inc. 168,000
2017-02-14 13G/A ADMP / Adamis Pharmaceuticals Corp 1,318,630 1,051,063
2017-02-14 13G/A QTNT / Quotient Ltd 1,789,156 2,237,771
2017-02-14 13G/A MTEM / Molecular Templates, Inc. 4,003,992 0
2016-02-16 13G/A QTNT / Quotient Ltd 1,789,156
2016-02-16 13G/A ADMP / Adamis Pharmaceuticals Corp 1,318,630
2016-02-16 13G MTEM / Molecular Templates, Inc. 4,003,992
2015-02-17 13G ADMP / Adamis Pharmaceuticals Corp 1,168,566
2015-02-17 13G QTNT / Quotient Ltd 1,656,449
2014-12-05 13G ADMP / Adamis Pharmaceuticals Corp 1,168,566